Skip directly to content

Partnership between health department leadership and community advocates is integral to the success of EtE initiatives. The advent of TasP and PrEP was a significant part of the first call to end HIV as an epidemic in New York. However, it was a renewed spirit of cooperation between the New York City Department of Health and Mental Hygiene, the New York State Department of Health, and community advocates that provided the opportunity to turn hopeful science into an implementable reality.

Aligning the priorities of state and city health departments with the priorities of the communities they

In 2014, Governor Cuomo announced a three-point plan to end HIV/AIDS as an epidemic in the state. In 2015, a task force appointed by the Governor developed – with extensive input from a parallel ad hoc community “kitchen cabinet” coalition – the New York State Blueprint which includes 30 key recommendations. Several metrics are being tracked in order to assess progress on recommendations from the plan, many of which can be tracked via the online EtE Dashboard.

The New York State AIDS Institute uses nine population-level metrics to help track progress toward Ending the Epidemic by 2020.

January 25, 2018

Gregg H. Alton
Executive Vice President
Corporate and Medical Affairs
Gilead Sciences
333 Lakeside Drive
Foster City, CA 94404

Dear Gregg:

A deeply concerning issue has been brought to our attention: Gilead Sciences is limiting access to Truvada (tenofovir disoproxil plus emtricitabine) as a component of nonoccupational postexposure prophylaxis (nPEP) through its patient assistance program (PAP) to once in a lifetime, with hardship review criteria and processes for subsequent prescriptions that have not been clearly articulated and are likely a considerable barrier to nPEP by

PIpeline Report 2018
July 23, 2018 – Treatment Action Group’s annual review of therapeutics, diagnostics, vaccines, and preventive technologies in development for HIV, hepatitis C virus (HCV), and tuberculosis, along with immune-based and gene therapies and research toward a cure for HIV.

TAGline, Spring 2018
April 4, 2018 – In this issue of TAGline, we highlight some important recent successes and challenges in meeting TAG’s overarching goals: moving beyond achingly slow trends and sharply bending the curves on new HIV, hepatitis C, and tuberculosis infections, suffering, and deaths.


January 19, 2018 – Treatment Action Group is alarmed by recent actions taken by the Trump administration to subvert the health and wellbeing of women, transgender individuals, and marginalized communities in America. At a time where science has made it possible to end the HIV, hepatitis C, and tuberculosis epidemics in our country, the anti-health, anti-science politics of the GOP and the White House are aggressively undermining what should otherwise be a proactive time in reducing the substantial national burden of these three diseases.

The proposed rule creating the “Conscience and

Webinar: Good COPs or Bad COPs? Advocacy to Ensure the Prioritization of TB in 2018 PEPFAR Country Operational Plans (COPs)

Good COPs or Bad COPs: Advocacy to Ensure the Prioritization of TB in 2018 PEPFAR Country Operational Plans (COPs).

Every year, PEPFAR meets to discuss their strategy and budget for the following year, and set targets on implementing country operation plans (COPs) to improve the response to HIV/AIDS. This year PEPFAR is engaging civil society earlier than in past years to help inform key decisions throughout the process—but the timeline is tight.

January 16, 2018 – “Because I was incensed!” With these words in a November 1984 interview with The New York Times, Dr. Mathilde Krim explained why she cofounded the AIDS Medical Foundation in 1983, the first private organization concerned with fostering and supporting AIDS research. She would go on to become the founding chair and chairman of the board of amfAR, the Foundation for AIDS Research, and an unparalleled champion of the science, policies, education, and compassion required to protect the lives of all people living with and vulnerable to HIV.


January 10, 2018 – The Tuberculosis Trials Consortium (TBTC) is a global leader in research and development for better tools to prevent, diagnose, and treat tuberculosis (TB). Housed within the U.S. Centers for Disease Control and Prevention (CDC), the TBTC conducts clinical research of high public health relevance and is key to strengthening domestic and global campaigns to eliminate TB. TBTC studies have produced several notable breakthroughs, including a shorter regimen for preventing TB (3HP) using isoniazid and rifapentine. The Community Research Advisors Group (CRAG) produced this

January 5, 2018 – In advance of a U.S. Senate Committee on Finance hearing on January 9, 2018, TAG and over 60 other civil society organizations issued a statement asking U.S. senators to oppose the confirmation of Alex Azar as Secretary of Health and Human Services, citing Azar's industry track-record and stances that counter public health and racial, gender, and economic justice. While Azar was president of Lilly USA, insulin costs nearly tripled.

February 2018 — TAG is seeking to hire a Finance Manager who will report to the Deputy Executive Director – Development and Operations (DED-DO). The Finance Manager will ensure timely and accurate development, management, and reporting of TAG's financials. They will work closely with the DED-DO, Executive Director (ED), Administrator, and Program Directors, and attend Board Finance Committee meetings on a monthly basis or as requested.

The Finance Manager's role requires tact, diplomacy, and interaction with staff and the Board. Strong communications skills, written and verbal, are a must.